Sponsor

Seagen Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Seagen Inc. appears in 42 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials42
Recruiting shown6
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

42 shown
A Safety Study of Brentuximab Vedotin in Participants With HIVNCT05244473 · lead sponsor · 2022-12-31
WITHDRAWN
A Study of SGN-ALPV in Advanced Solid TumorsNCT05229900 · lead sponsor · 2022-04-21
TERMINATED
A Study of SEA-CD40 Given With Other Drugs in CancersNCT04993677 · lead sponsor · 2021-10-06
COMPLETED
A Study of SGN-STNV in Advanced Solid TumorsNCT04665921 · lead sponsor · 2021-01-18
TERMINATED
A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerNCT04254107 · lead sponsor · 2020-05-29
TERMINATED
A Study of Ladiratuzumab Vedotin in Advanced Solid TumorsNCT04032704 · lead sponsor · 2019-10-09
TERMINATED
A Study of SGN-CD228A in Advanced Solid TumorsNCT04042480 · lead sponsor · 2019-09-03
TERMINATED
A Safety Study of SGN-CD47M in Patients With Solid TumorsNCT03957096 · lead sponsor · 2019-07-17
TERMINATED
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast CancerNCT03310957 · lead sponsor · 2018-02-27
COMPLETED
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.NCT03245736 · lead sponsor · 2017-08-23
COMPLETED
A Safety Study of SGN-2FF for Patients With Advanced Solid TumorsNCT02952989 · lead sponsor · 2017-02-23
TERMINATED
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerNCT02614794 · lead sponsor · 2016-01-28
COMPLETED
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsNCT02552121 · lead sponsor · 2015-11-30
COMPLETED
Safety Study of SEA-CD40 in Cancer PatientsNCT02376699 · lead sponsor · 2015-02-28
TERMINATED
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast CancerNCT01983501 · lead sponsor · 2014-02-28
COMPLETED
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast CancerNCT02025192 · lead sponsor · 2013-12-31
COMPLETED
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsNCT02001623 · lead sponsor · 2013-11-30
COMPLETED
A Safety Study of SGN-LIV1A in Breast Cancer PatientsNCT01969643 · lead sponsor · 2013-10-22
COMPLETED
FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung CarcinomaNCT00086333 · lead sponsor · 2004-07-01
COMPLETED
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate CancerNCT00031187 · lead sponsor · 2000-10-01
COMPLETED
Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast CancerNCT00028483 · lead sponsor · 2000-10-01
TERMINATED
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast CancerNCT03424473 · lead sponsor
NO_LONGER_AVAILABLE
Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung CarcinomaNCT00051571 · lead sponsor
COMPLETED
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast CancerNCT05955170 · collaborator · 2023-12-19
RECRUITING
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 StudyNCT06162559 · collaborator · 2023-12-18
RECRUITING
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseNCT05800275 · collaborator · 2023-12-18
RECRUITING
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerNCT05748834 · collaborator · 2023-07-24
RECRUITING
Metastatic Breast Cancer in AustriaNCT03870620 · collaborator · 2015-06-15
RECRUITING
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008NCT03275311 · collaborator · 2014-07-01
RECRUITING
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the BrainNCT05892068 · collaborator · 2023-05-09
ACTIVE_NOT_RECRUITING
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast CancerNCT05583110 · collaborator · 2023-03-08
TERMINATED
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.NCT05230810 · collaborator · 2022-08-25
ACTIVE_NOT_RECRUITING
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain MetastasesNCT04512261 · collaborator · 2022-06-01
WITHDRAWN
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast CancerNCT05227131 · collaborator · 2022-05-15
WITHDRAWN
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerNCT05319873 · collaborator · 2022-04-07
ACTIVE_NOT_RECRUITING
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast CancerNCT05041842 · collaborator · 2021-12-17
ACTIVE_NOT_RECRUITING
Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.NCT04896320 · collaborator · 2021-12-15
WITHDRAWN
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)NCT04700124 · collaborator · 2021-04-21
ACTIVE_NOT_RECRUITING
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · collaborator · 2021-03-02
ACTIVE_NOT_RECRUITING
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)NCT04225117 · collaborator · 2020-03-10
ACTIVE_NOT_RECRUITING
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMDNCT03501979 · collaborator · 2019-02-20
TERMINATED
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate CancerNCT01228760 · collaborator · 2010-10-01
COMPLETED

Sponsor roles

lead sponsor23
collaborator19
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.